Rapamycin and Longevity: What the Latest Human Trials Actually Show
The most robust life-extending drug in animal models is now being tested in humans. Here is a breakdown of the evidence, the uncertainties, and the results of the year-long PEARL trial.
By Factlen Editorial Team
Geroscience Researchers 40%Clinical Skeptics 30%Longevity Medicine Practitioners 30%
- Geroscience Researchers
- Focus on the robust animal data and the biological mechanism of mTOR inhibition, advocating for continued clinical trials to translate these findings to humans.
- Clinical Skeptics
- Emphasize the lack of long-term human mortality data, the failure to meet primary endpoints in trials, and the risks of widespread off-label use.
- Longevity Medicine Practitioners
- Point to the safety profile of low-dose weekly administration and early signals of healthspan improvement to justify careful off-label prescription.
What's not represented
- · Regulatory agencies evaluating off-label use
- · Patients experiencing adverse effects from off-label use
Why this matters
Rapamycin is the most consistently proven life-extending compound in animal models, and its off-label use in humans is surging. Understanding what the clinical data actually supports—and where the evidence falls short—is critical for anyone considering longevity interventions.
More in health
See all 125 stories →Peptide Therapy
How Experimental Peptides Moved From Niche Biohacking to Mainstream Wellness
8 sources
Nutritional Psychiatry
The Evidence for Nutritional Psychiatry: How Diet Modifies Mental Health
7 sources
Sleep Science
How Temperature and Light Optimize Deep Sleep and Brain Health
7 sources
CAR-T Therapy
CAR-T Cell Therapy Puts Severe Lupus Into Remission in UK Trial
7 sources
Stay informed
Every angle. Every day.
Get health stories with full source coverage and perspective breakdowns delivered to your inbox.